Kornimate/medical-research-clean huggingface dataset:
a study evaluating vitamin d in allergic bronchopulmonary aspergillosis complicating asthma

Conditions: Allergic Bronchopulmonary Aspergilloses

Summary: allergic bronchopulmonary aspergillosis (abpa) is a immunological pulmonary disorder caused by hypersensitive reaction to spores of aspergillus fumigatus. the prevalence of disease is about 1-2% in asthmatics and 2-15% in patients with cystic fibrosis. the interest in abpa stems from the fact that the disease is glucocorticoid-sensitive and early treatment can prevent progression to end-stage lung disease. recently anti-th2 therapies have been suggested as treatment for abpa. vitamin d has been shown to suppress the th2 responses and decrease the levels of th2 interleukins. hence, the investigators propose to assess the role of vitamin d in treating abpa.

allergic bronchopulmonary aspergillosis (abpa) is a immunological pulmonary disorder caused by hypersensitive reaction to spores of aspergillus fumigatus. the prevalence of disease is about 1-2% in asthmatics and 2-15% in patients with cystic fibrosis. the interest in abpa stems from the fact that the disease is glucocorticoid-sensitive and early treatment can prevent progression to end-stage lung disease. systemic steroids remain the mainstay of treatment in abpa. antifungal agents are also useful as they reduce fungal load. newer therapies like omalizumab (anti immunoglobulin e \[ige\] antibody), inhalational amphotericin and anti th2 therapies are being studied. in pathogenesis of abpa, there is heightened th2 activity as a result of type 1 hypersensitive reaction to aspergillus fumigatus and levels of th2 cytokines like il-3, il-5 and il-13 and ige levels are increased in patients with abpa compared with asthma patients without abpa. recently anti th2 therapies have been suggested as treatment for abpa. vitamin d has been shown to suppress the th2 immunity and decrease the levels of th2 interleukins. hence, the investigators propose to assess the role of vitamin d in treatment of abpa.

Eligibility criteria:
inclusion criteria: * diagnosis of abpa as per the international society for human and animal mycology working group criteria * treatment naïve exclusion criteria: * failure to provide informed consent * enrollment in another trial of abpa * pregnancy * creatinine more than or equal to 1.5 mg/dl * immunosuppressive states like chronic liver disease, chronic renal failure, cytotoxic therapy, uncontrolled diabetes mellitus and others
losartan in decompensated heart failure

Conditions: Congestive Heart Failure; Low Cardiac Output

Summary: the dual blockade of the renin-angiotensin-aldosterone system with an angiotensin-converting enzyme inhibitor and an angiotensin-receptor blocker used together in heart failure patients has been demonstrated to be beneficial. however, the dual inhibition has not been studied during heart failure decompensation or even when low cardiac output is present. the objective of this study was to assess the effects of add-on therapy with angiotensin receptor blocker on plasma b-type natriuretic peptide levels and hemodynamic measurements in heart failure patients with low cardiac output during hospitalization for decompensation. this was a randomized, double-blind, placebo-controlled clinical trial.

the inclusion criteria were hospitalization for decompensated heart failure defined by worsening of symptoms until fatigue or dyspnea at rest, low cardiac output defined by the clinical-hemodynamic profile, dobutamine dependence, and ejection fraction \< 0.45, spontaneous breathing and receiving angiotensin-converting enzyme inhibitors. the patients could have jugular ingurgitation, lower limbs edema, ascites and rales. dobutamine dependence was defined by infusion for more than 15 days or an unsuccessful attempt of withdrawal. the exclusion criteria were serum creatinine \> 3.0 mg/dl, serum potassium \> 6.0 meq/l, systolic blood pressure \< 70 mm hg, aortic stenosis, and acute coronary syndrome in the previous 2 months. the patients were randomly assigned by permuted block of 4, stratified by sex, to losartan or placebo. the endpoints were change in b-type natriuretic peptide levels, cardiac index, pulmonary wedge capillary pressure, systemic vascular resistance, and successful withdrawal of dobutamine.

Eligibility criteria:
inclusion criteria: * hospitalization for decompensated heart failure * dobutamine dependence * ejection fraction \< 0.45 * taking angiotensin-converting enzyme inhibitor exclusion criteria: * serum creatinine \> 3.0 mg/dl * serum potassium \> 6.0 meq/l * systolic blood pressure \< 70 mm hg * aortic stenosis * acute coronary syndrome in the previous 2 months

Keywords: renin-aldosterone system hemodynamic low cardiac output vasodilation natriuretic peptide
oral dydrogesterone vs. micronized vaginal progesterone for luteal phase support in frozen-thawed embryo transfer cycles

Conditions: Infertility, Female; Infertility, Male; Embryo Transfer; Fertilization in Vitro; Drug Effect; Reproductive Techniques, Assisted; Progesterone; Dydrogesterone

Summary: the aim of this randomized controlled trial is to compare the efficacy of oral dydrogesterone vs. micronized vaginal progesterone for luteal phase support in frozen-thawed embryo transfer cycles.


Eligibility criteria:
inclusion criteria: * ages between 20 and 40 * modified natural frozen- thawed embryo transfer cycles exclusion criteria: * recurrent implantation failure * recurrent pregnancy loss * presence of uterine pathology

Keywords: oral dydrogesterone luteal phase support vaginal progesterone gel frozen-thawed embryo transfer
university of north carolina-healthwise partnership project on birth options decision aid

Conditions: Scar; Previous Cesarean Section; Vaginal Birth After Cesarean; Decision Making, Shared

Summary: this is pilot quasi-experimental study of women with one or two prior cesarean deliveries who are now pregnant and eligible for a trial of labor after cesarean delivery, to assess whether a decision aid, providing knowledge about trial of labor (vbac) and planned repeat cesarean delivery can improve the birth options decision-making process for patients. participants are screened for eligibility through electronic health records. once an individual is screened eligible, and email invite is sent providing information about the study and assessing the interest in participation. an on-line consent is completed and women are entered sequentially into the usual care group and then through further recruitment, another sample of women are entered into the decision aid group. the primary outcome is satisfaction with the shared decision-making process with their provider.

once a potential participant is screened eligible, completes the on-line informed consent, they are officially enrolled in the study and sent a link confirming their enrollment and the study group in which they have been assigned. participants are sequentially enrolled in the study with enrollment first into the usual care group. once enrollment in the usual care group is complete, enrollment into the decision aid group will occur. the study includes two non-randomized groups: arm 1 (usual care group): women in this group will undergo usual care and complete the survey questions on knowledge of risks and benefits of tolac (also referred to as vbac) and planned repeat cesarean (prcs), certainty of their decision, and involvement in the decision for trial of labor (tolac) or repeat cesarean delivery. arm 2: (decision aid group- group receiving the decision tool): women in this group will receive a decision aid prior to undergoing counseling by their physician. following completion of the decision aid and physician counseling, they will complete a series of survey questions to assess their knowledge of the risks and benefits of tolac and prcs, certainty of their decision, and involvement in the decision for repeat cesarean or tolac. the decision aid group will be compared with women who do not receive the decision aid (usual care group).

Eligibility criteria:
inclusion criteria: * gestational age between 19/0 and 36/6 weeks * history of 1 or 2 prior cesarean deliveries exclusion criteria: * no contraindications to trial of labor after cesarean (tolac) * no history of prior tolac
early vs late bladder dissection during cs hysterectomy in patients with pas with bladder invasion

Conditions: Placenta Accreta Spectrum; Cesarean Hysterectomy

Summary: thirty-six singleton pregnant women with pas and bladder invasion; total anterior or anterolateral invasion, who were scheduled for cesarean hysterectomy were randomly assigned into two equal groups * group 1: included 18 pregnant women scheduled for classical cesarean hysterectomy for placenta accreta with or without ligation of anterior division of internal iliac artery before cesarean section. * group 2: included 18 pregnant women scheduled for bladder last cesarean hysterectomy with or without ligation of anterior division of internal iliac artery.


Eligibility criteria:
inclusion criteria: 1. age: reproductive age. 2. pregnant with singleton living fetus. 3. previous one or more cesarean sections. 4. gestational age: \> 34 weeks. 5. elective or non-emergency cesarean sections. 6. preoperative hemoglobin more than 9.5 gm/dl. exclusion criteria: women with history of any medical disorder with pregnancy eg. gestational diabetes, hypertension, or anemia.
prone positioning for patients on general medical wards with covid19

Conditions: Covid-19; ARDS

Summary: covid-prone is a multicenter, pragmatic, unblinded, 2-arm, parallel, randomized controlled trial seeking to compare the pre-emptive prone positioning (i.e. encouraging patients to adopt a prone position before they require mechanical ventilation) to the control arm of standard care alone. randomization will be stratified by site.

covid-prone is a multicenter, pragmatic, unblinded, 2-arm, parallel, randomized controlled trial. the intervention is not a medication or a medical device. instead, the intervention is instructing patients to lie on their stomach while they are in bed. patients will be randomized to receive either standard-of-care or pre-emptive prone positioning while in bed plus standard of care. randomization will be stratified by site. patients randomized to prone positioning will be instructed to i) lie on their stomach supported by their arms and a pillow at the level of their shoulders and another pillow at the level of the pelvis, ii) immediately thereafter their oxygen saturation will be checked, iii) after a two hour period they can reposition to supine (but should be educated on the use of prone position and encouraged to adopt prone position as often as tolerated while in bed); the 2-hour period will be encouraged four times each day in addition to during sleep overnight. since there are limited data on the potential risks and benefits of prone positioning, a feasibility analysis will be performed after 30 patients are randomized to identify the rate of serious adverse events in the prone group (e.g., rate of pneumonia, death, intubation) and to understand the change in oxygenation as a result of prone positioning.

Eligibility criteria:
inclusion criteria: 1. patients ≥ 18 years of age 2. covid-19 infection is suspected by the treating clinician or confirmed by diagnostic test 3. able to lie on their stomach with verbal instruction 4. requiring supplemental oxygen less than or equal to 50% fio2 5. capable to make treatment related decisions 6. hospitalized in the last 48 hours with suspected or confirmed covid-19 infection or diagnosed for nosocomial infection in the last 48 hours during their hospital stay exclusion criteria: 1. inability to follow commands (e.g., delirium, dementia) 2. indication for mechanical ventilation (e.g., reduced level of consciousness, rapid clinical deterioration) 3. contraindication to prone positioning (spinal cord injury, unstable c-spine, pelvic fracture, unstable airway, open chest or abdomen, anterior chest tube, recent abdominal surgery in past 14 days) 4. patients on home cpap (continue positive airway pressure) 5. transfer from icu in past 72 hours 6. need for telemetry at the time of randomization 7. pregnant (i.e., more than 20 weeks) 8. body mass index above 40 kg/m2 (based on clinician's assessment) 9. recently completed or plan for intrathoracic or intra-abdominal surgical procedure 10. severe hemoptysis 11. pace-maker inserted in past 48 hours
a study to assess the effects of freshly fit meals on body weight and wellness in overweight and obese adults

Conditions: Weight Loss

Summary: the primary objective of this trial is to examine the weight-loss efficacy of freshly fit meals, as well as body composition, waist/hip circumference, metabolic markers, and quality of life in overweight and obese adults.


Eligibility criteria:
inclusion criteria: * male or female, 21-55 years of age, inclusive, at visit 1 (day -10). * bmi of 25.00 to 34.99 kg/m2, inclusive, at visits 1 and 2 (day -10 and -3). * non-smoker and has no plans to change smoking habits during the study period. * willing to follow study instructions. * willing and able to comply with the visit schedule (e.g., subjects with travel plans and cannot fully comply with study instructions will be excluded). exclusion criteria: * abnormal laboratory test result of clinical significance at visit 1 (day -10), at the discretion of the investigator. one re-test will be allowed on a separate day prior to visit 2 (day -3) for subjects with abnormal laboratory test results. * history or presence of clinically important cardiac, renal, hepatic, endocrine, pulmonary, biliary, pancreatic, or neurological disorders that may affect the subject's ability to adhere to the study protocol and/or affect study outcomes, in the judgment of the investigator. * history of gastrointestinal surgery for weight reducing purposes. * participation in a weight loss trial within 12 mo of visit 1 (day -10). * weight loss or gain ≥10 lb (4.5 kg) within the 6 mo prior to visit 1 (day -10). participation in a program/service intended to alter body weight (e.g., nutrisystem, weight watchers, noom) within 6 mo of visit 1 (day -10).
triggering oocyte maturation in normoresponders using double trigger or hcg trigger

Conditions: Infertility

Summary: the aim of this study is to compare the efficacy double trigger \[ co-administration of gnrh agonist with hcg 40 and 34 h prior to ovum pick-up, respectively\] with hcg trigger in inducing oocyte maturation.

several studies revealed that the double trigger regimen was effective in the treatment of patients with a history of immature oocytes retrieved or with suboptimal oocytes yield. the investigators designed this randomized controlled trial to compare the efficacy double trigger with hcg trigger in inducing oocyte maturation.in normoreponders undergoing ivf-et

Eligibility criteria:
inclusion criteria: * normoresponders * gnrh antagonist cycles exclusion criteria: * bmi more than 35 * endometriosis * amh less than 1.1 ng * amh more than 4 * pcos * poor responders

Keywords: infertility ivf-et hcg trigger double trigger
pharmacokinetic properties of rasagiline (lu 00-773) in healthy young chinese men and women

Conditions: Parkinson's Disease

Summary: the purpose of this study is to fulfil regulatory requirements for registration of a new chemical entity in china. rasagiline is approved for the treatment of parkinson's disease (pd) in europe and the us. rasagiline is safe and well tolerated in healthy subjects, and the efficacy and safety has been demonstrated in placebo- and active comparator-controlled phase iii studies.


Eligibility criteria:
inclusion criteria: * the subject is a chinese man or woman * the subject is, in the opinion of the investigator, generally healthy * if female, the subject must have a negative pregnancy test at screening and baseline, and agree not to try to become pregnant from screening until after the follow-up visit exclusion criteria: * the subject is, in the opinion of the investigator, unlikely to comply with the clinical study protocol or is unsuitable for any other reason. other inclusion and exclusion criteria may apply.
potential impact of cigarette smoking on platelet reactivity in patients on dual antiplatelet therapy with p2y12 inhibitors

Conditions: Coronary Artery Disease

Summary: all consecutive patients undergone ptca in the period between july 2013 and december 2013 are eligible to be enrolled. study population are divided in : group 1: smokers on dual antiplatelet therapy with asa (100 mg once a day) and prasugrel (10 mg die); group 2: smokers on dual antiplatelet therapy with asa(100 mg once a day) and ticagrelor (90 mg twice a day); control group: smokers on dual antiplatelet therapy with asa(100 mg once a day) and clopidogrel (75 mg once a day). platelet function is evaluated using a validated method: the verifynow system (accumetrics inc., san diego, ca), which is a point-of-care turbidimetry-based optical detection system that measures platelet-induced aggregation. these value are measured platelet function, measured with the verifynow p2y12. all patients on chronic dual antiplatelet therapy (\>1 month) quit smoking for a 2 weeks period. therefore pru values are obtained at baseline (at the enrollment time) and after 2 weeks after smoking cessation. platelet reactivity are expressed in p2y12 reaction units (pru). pru values \>240 are suggestive of high platelet reactivity. primary outcomes: p2y12 reaction units (pru) at baseline and two weeks after quitting smoking.

all consecutive patients undergone ptca in the period between july 2013 and december 2013 are eligible to be enrolled. study population are divided in : group 1: smokers on dual antiplatelet therapy with asa (100 mg once a day) and prasugrel (10 mg die); group 2: smokers on dual antiplatelet therapy with asa(100 mg once a day) and ticagrelor (90 mg twice a day); control group: smokers on dual antiplatelet therapy with asa(100 mg once a day) and clopidogrel (75 mg once a day). platelet function is evaluated using a validated method: the verifynow system (accumetrics inc., san diego, ca), which is a point-of-care turbidimetry-based optical detection system that measures platelet-induced aggregation. these value are measured platelet function, measured with the verifynow p2y12. all patients on chronic dual antiplatelet therapy (\>1 month) quit smoking for a 2 weeks period. therefore pru values are obtained at baseline (at the enrollment time) and after 2 weeks after smoking cessation. platelet reactivity are expressed in p2y12 reaction units (pru). pru values \>240 are suggestive of high platelet reactivity. primary outcomes: p2y12 reaction units (pru) at baseline and two weeks after quitting smoking.

Eligibility criteria:
inclusion criteria: * all consecutive patients undergone ptca in our institution in the period between july 2013 and december 2013 will be eligible to be enrolled. * smokers will be all patients smoking 15±10 cigarettes daily. * patients on dual antiplatelet therapy with asa and p2y12 inhibitors. * recent (\<12 months) percutaneous coronary interventions * angiographically-proven coronary artery disease exclusion criteria: - people unable to understand and willing to sign the informed consent form
characterization of dermal reactions in pediatric patients with adhd using daytrana

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this is a study designed to characterize the dermal response of daytrana. subjects will visit the study site over a period of approximately 14 weeks.

this is a study designed to characterize the dermal response of daytrana. subjects will visit the study site over a period of approximately 14 weeks. subjects will be titrated to an optimum dose of study treatment and assessed for safety and efficacy. dermal response will be evaluated at each visit by the investigator. subjects with high dermal response scores or scores that persist at the same application site and have no improvement after up to 4 evaluations (not to exceed a two week period) will be discontinued from the study and referred to a study specific dermatologist for specialized skin sensitivity skin patch testing.

Eligibility criteria:
inclusion criteria: * must sign informed consent. * male or female 6-12 years old. * negative pregnancy test. * meet diagnostic and statistical manual of mental disorders, 4th edition - text revision (dsm-iv-tr) criteria for a primary diagnosis of adhd. * no co-morbid illness that could affect safety, tolerability or interfere with participation. * blood pressure (bp) within the 95th percentile for age, gender, and height. * willing and able to comply with all the requirements defined in protocol. exclusion criteria: * current controlled (requiring a restricted medication) or uncontrolled co-morbid psychiatric diagnosis (except oppositional defiant disorder \[odd\]). * at risk for suicidal or violent behavior towards self or others. * history of a suicide attempt. * history of a structural cardiac abnormality or other serious cardiac problems. * non-responder to psychostimulant treatment. * is overweight. * seizures during the last 2 years (exclusive of infantile febrile seizures), a tic disorder, a current diagnosis and/or family history of tourette's disorder. * has conduct disorder. * known history of alcohol or other substance abuse within the last 6 months. * any abnormal thyroid function. * a concurrent chronic or acute illness, disability, or other condition that might confound results of safety assessments. * has had treatment with any known liver altering agents within 30 days prior to screening. * taking any excluded medication. * previous use of daytrana. * taking other medications that have central nervous system (cns) effects. * female subject is pregnant or lactating. * has any skin disease, or history of any chronic skin disease, skin cancer, skin manifestations of allergic disease, or other dermatologic conditions. * has sensitive-skin syndrome or has sensitivities to the ingredients in soaps, lotions, cosmetics or adhesives. * has clinical signs and symptoms of skin irritation or hyper/hypopigmentation at the potential application sites. * a documented allergy, hypersensitivity or intolerance of methylphenidate (mph) or any components found in daytrana.